FDA OK for Cepheid's Xpert MRSA tests
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for two of Cepheid’s diagnostics for the detection of Staphylococcus aureus (SA) and methicillin-resistant S aureus (MRSA). The first was for its Xpert MRSA/SA SSTI (skin and soft tissue infections) test, which detects the bacteria in suspicious wounds or skin infections. The second is the Xpert MRSA/SA BC (blood culture) test, which detects the bacteria in Gram-positive blood culture bottles in patients with signs of life-threatening bloodstream infections. Both diagnostics produce results in under an hour, run on the GeneXpert System, and cost $75. Existing blood culture tests take up to 48 hours and patients receive broad-spectrum antibiotics in the interim which could lead to resistance, Sunnyvale, California-based Cepheid says.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.